中文

Shunlong Wang
Ph.D

Chairman and Founder

Li Sheng
M.B.A

Founding Managing Partner

Minchuan Wang
Ph.D

Founding Managing Partner

Shunlong Wang
Ph.D

Chairman and Founder

Over 25 years of experience in healthcare investment and private equity fund management

Founded 3H Health Investment in July 2016

Prior to founding 3H, Mr. Wang worked at Hony Capital from January 2005 to June 2015. He served as Partner and Managing Director and Executive Committee Member in Hony Capital

Former executive director of CSPC Pharmaceutical Group (1093.HK) and non-executive director of Consun Pharmaceutical Group (1681.HK)

Key investments include CSPC (1093.HK), Simcere (2096.HK), Consun (1681.HK), YiXinTang (002727.SZ), Dihon (acquired by Bayer AG) etc.

Education and Recognitions

Peking University International Research Centre of Medicinal Administration Senior Fellow

Visiting Scholar at Eindhoven University of Technology in the Netherlands

PhD and Bachelor’s degree in Mechanical Engineering from Tsinghua University

Li Sheng
M.B.A

Founding Managing Partner

Over 17 years of practical investment experience in medicine, medtech, and medical services sectors

Co-founded 3H Health Investment in July 2016

Prior to founding 3H, Mr. Sheng worked at Hony Capital from 2006 to 2016, including 4 years as the Director of the Healthcare Department

Prior to Hony Capital, Mr. Sheng spent 4 years at AstraZeneca

Key investments include CSPC (1093.HK), CanSinoBIO (6185.HK), SQ Medical, HEMO, MicroPort CardioFlow (2160.HK), Edge Medical Robotics, Healthy Life Innovation Medical, Reliable Med, Hangzhou JustHealth Technology, Chamlion etc.

Education and Recognitions

M.B.A from Tsinghua University

B.A in Biomedical Sciences from China Pharmaceutical University

Minchuan Wang
Ph.D

Founding Managing Partner

Over 14 years of investment experience in healthcare. Active investor specialized in global biopharmaceutical and biotech sectors

Co-founded 3H Health Investment in July 2016

Prior to founding 3H, Mr. Wang worked at the Healthcare Department of Hony Capital from 2009 to 2016, mainly covering the biopharmaceutical sector

Key investments include CSPC (1093.HK), InnoCare (9969.HK), KeyMed Bio, Alebund, Haihe Pharma, EdiGene, Triapex, Kanova Bio, Angitia Bio etc.

Education and Recognitions

Hong Kong Exchanges and Clearing Limited (HKEX) Biotech Advisory Panel Member; Hong Kong SAR Innovation and Technology Fund Panel Member

Peking University International Research Centre of Medicinal Administration Senior Fellow

PhD and MPhil in Biomedical Sciences from University of Cambridge

Bachelor’s degree from Peking University Medical School

Important Notice

Recently, it has come to our attention that certain individuals that have impersonated 3H to publish fake and misleading information and carry out illegal activities such as financing and capital raising via websites, apps and other channels.

3H hereby declares:

1.“三正健康”, “三正健康投资”, “3H HEALTH”, “3H”, “3h partner”, “3h health”are all legally registered by our company (including our affiliated parties), and shall not be used illegally by anyone without our permission.

2.3H official contact information is as follows. If you have any further questions, please visit our official website or call +86 21 6107 2498

a.Official Website: www.3hhinvestment.com;

b.Official WeChat Account: 3H Health Investment (WeChat ID: 三正健康投资)

c.Official LinkedIn Account: https://www.linkedin.com/company/3h-health-investment-management/

3.3H Health Investment has never authorized and will never authorize any entity or individual to conduct any public fundraising activities in the name of 3H Health through any channels such as websites, apps, WeChat, and Weibo.

All individuals and groups participating in the above activities are involved in illegal capital raising. We disclaim any legal or commercial relationships thereof. These illegal activities have seriously damaged 3H’s reputation, and we reserve the right to take legal actions against the above-mentioned entities and individuals. Please stay alert to false information to avoid any financial loss.